Recommendations for the treatment of lipid disorders in patients on peritoneal dialysis

Peritoneal Dialysis International

Volumn 19, Issue 1, 1999, Pages 7-16

  Fried, Linda ^a   Hutchison, Alastair ^b   Stegmayr, Bernd ^c   Prichard, Sarah ^d   Bargman, Joanne M ^e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOPROTEIN; CHOLESTEROL; COLESTYRAMINE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIET SUPPLEMENTATION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0032938183     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901900103     Document Type: Review

References (71)

1. Dahlen G, Guyton JR, Arrar M, Farmer JA, Kautz JA, and Gotto AM. Association of levels of lipoprotein(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74:758-65.
2. Attman P, Samuelsson O, and Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21:573-92.
3. Norbeck HE, Carlson LA. The uremic dyslipoproteinemia: its characteristics and relations to clinical factors. Acta Med Scand 1981; 209:489-503.
4. Bergesio F, Monzani G, Ciuti R, Serruto A, Benucci A, Frizzi V, et al. Lipids and apolipoproteins change during the progression of chronic renal failure. Clin Nephrol 1992; 38:264-70.
5. Gruber KK, Hoffner SM, Tuttle KR. Increased Lp(a) concentrations in chronic renal failure. J Am Soc Nephrol 1992; 3:333.
6. Anwar N, Bhatnagar D, Short CD, Mackness MI, Durrington PN, Prais H, et al. Serum lipoprotein(a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8:71-4.
7. Akmal M, Kasim SE, Soliman AR, Massry SG. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 1990; 37:854-8.
8. Wheeler DC. Abnormalities of lipoprotein metabolism in CAPD patients. Kidney Int 1996; 50(Suppl 56): S41-6.
9. Lacour B, Roullet J, Beyne P, Kreis H, Thevenin M, Drueke T. Comparisons of several atherogenicity indices by the analysis of serum lipoprotein composition in patients with chronic renal failure with or without hemodialysis, and in renal transplant patients. J Clin Chem Clin Biochem 1985; 23:805-10.
10. Avram MM, Fein PA, Antignani A, Mittman N, Mushnick RA, Lustig AR, et al. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and CAPD. Am J Med 1989; 87:55N-60N.
11. Lindholm B and Norbeck HE. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand 1986; 220:143-51.
12. Horkko S, Huttunene K, Laara E, Kerinen K, and Kesaniemi YA. Effects of three treatment modes on plasma lipids and lipoproteins in uremic patients. Ann Med 1994; 26:271-82.
13. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 1995; 10:354-7.
14. Siamopoulos KC, Elisaf MS, Bairaktari HT, Pappas MB, Sferopoulos GD, Nikolakakis NG. Lipid parameters including lipoprotein(a) in patients undergoing CAPD and hemodialysis. Perit Dial Int 1995; 15:342-7.
15. Llopart R, Donate T, Olivia JA, Roda M, Rousaud F, Gonzalez-Sasatre F, et al. Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients. Nephrol Dial Transplant 1995; 10:537-40.
16. Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N. The uremic dyslipidemia: a cross-sectional and longitudinal study. Am J Kidney Dis 1992; 20:324-35.
17. Kawaguchi Y, Kubo H, Yamamoto H, Nakayama M, Yokoyama K, Shigematsu T, et al. Is atherosclerosis accelerated by CAPD? Perit Dial Int 1996; 16(Suppl 1):S223-30.
18. Ramos JM, Heaton A, McGurk JG, Ward MK, and Kerr DNS. Sequential changes in serum lipids and their subfractions in patients receiving CAPD. Nephron 1983; 35:20-3.
19. Kagan A, Bar-Khayim Y, Schafer Z, and Fainaru M. Kinetics of peritoneal protein loss during CAPD: lipoprotein leakage and its impact on plasma lipid levels. Kidney Int 1990; 37:980-90.
20. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, and Morii H. High serum lipoprotein(a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 1992; 38:271-6.
21. Murphy BG, McNamee P, Duly E, Henry W, Archbold P, and Trinick T. Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis. Atherosclerosis 1992; 93:53-7.
22. Khanna R, Wu G, Vas S, Oreopoulos DG. Mortality and morbidity on continuous ambulatory peritoneal dialysis. ASAIO J 1983; 6:197-204.
23. Lupo A, Tarchini R, Cancarini G, Catizone L, Cocchi R, De Vecchi A, et al. Long-term outcome in continuous ambulatory peritoneal dialysis: a 10 year survey by the Italian Cooperative Peritoneal Dialysis Study Group. Am J Kidney Dis 1994; 24: 826-37.
24. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996; 7:198-207.
25. Nicholls AJ, Catto GRD, Edward N, Engeset J, Macleod M. Accelerated atherosclerosis in long-term dialysis and renal transplant patients: fact or fiction? Lancet 1980; 1:276-8.
26. Prichard S, Sniderman A, Cianflone K, Marpole D. Cardiovascular disease in peritoneal dialysis. Perit Dial Int 1996; 16(Suppl 1):S19-22.
27. Rostand SG, Brunzell JD, Cannon III RO, Victor RG. Cardiovascular complications in renal failure. J Am Soc Nephrol 1991; 2:1053-62.
28. Tschope W, Koch M, Thomas B, Ritz E, and the German Study Group Diabetes and Uremia. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Nephron 1993; 64:354-8.
29. Lowrie EG, Huang WH, Lew NL. Death risk predictors among peritoneal dialysis and hemodialysis patients: a preliminary comparison. Am J Kidney Dis 1995; 26:220-8.
30. Piccoli GB, Quarello F, Salomone M, Iadarola GM, Funaro L, Marciello A, et al. Are serum albumin and cholesterol reliable outcome markers in elderly dialysis patients? Nephrol Dial Transplant 1995; 10(Suppl 6):72-7.
31. Pollock CA, Ibels LS, Caterson RJ, Mahoney JF, Waugh DA, Cocksedge B. Continuous ambulatory peritoneal dialysis: eight years of experience at a single center. Medicine 1989; 68:293-308.
32. Gault MH, Longerich L, Prabhakaran V, Purchase L. Ischemic heart disease, serum cholesterol and apolipoproteins in CAPD. ASAIO Trans 1991; 37:M513-14.
33. Gamba G, Mejia JL, Saldivar S, Pena JC, Correa-Rotter R. Death risk in CAPD patients: the predictive value of the initial clinical and laboratory values. Nephron 1993; 65:23-7.
34. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986; 256:2835-8.
35. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med 1997; 62:707-14.
36. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol levels: a meta-analysis of population based prospective studies. J Cardiovasc Risk 1996; 3:213-19.
37. Committee of Principal Investigators. WHO Cooperative Trial on primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol: final mortality follow up. Lancet 1984; 2:600-4.
38. Lipid Research Clinics Program. The Lipids Research Clinics coronary primary prevention trial results: reduction in incidence of coronary heart disease. JAMA 1984; 251:351-63.
39. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary prevention trial with gemfibrizol in middle-aged men with dyslipidemia. N Engl J Med 1987; 317:1237-45.
40. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/L (200 to 300 mg/dL) plus two additional atherosclerotic risk factors. Am J Cardiol 1993; 72:1031-7.
41. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, McFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study. N Engl J Med 1995; 333:1301-7.
42. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-81.
43. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223:405-18.
44. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383-9.
45. Manninen V, Huttunen JK, Heinonen OP, Tenkanen L, Frick MH. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am J Cardiol 1989; 63:42H-47H.
46. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anti-coagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med 1997; 336:153-62.
47. Gokal R, Mann J, Oliver D, Ledingham J. Dietary treatment of hyperlipidemia in chronic hemodialysis patients. Am J Clin Nutr 1978; 31:1915-18.
48. Cattran D, Steiner G, Fenton S, Ampil M. Dialysis hyperlipidemia: response to dietary manipulation. Clin Nephrol 1980; 13:177-82.
49. Massy Z, Ma J, Louis T, and Kasiske B. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48:188-98.
50. Dimitriadis A, Antonious S, Hatzisawas N, Pasture F, Kaldi I, Stangou M. The effect of simvastatin on dyslipidemia in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993; 13(Suppl 2):S434-6.
51. Balaskas E, Bamihas G, Tourkantonis A. Management of lipid abnormalities in patients on CAPD (Letter). Perit Dial Int 1997; 17:308-9.
52. van Acker BAC, Bilo HJG, Popp-Snijders C, Van Bronswijk H, Oe LP, Donker AJM. The effect of fish oil on lipid profile and viscosity of erythrocyte suspensions in CAPD patients. Nephrol Dial Transplant 1987; 2:557-61.
53. Jones RG, Dibble JB, Gibson J, Tompkins L, O'Kane M, Hobson SM, et al. Effect of dietary fish oil on lipid abnormalities in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1988; 8:203-6.
54. Lempert KD, Rogers II JS, Albrink MJ. Effects of dietary fish oil on serum lipids and blood coagulation in peritoneal dialysis patients. Am J Kidney Dis 1988; 11:170-5.
55. Goren A, Stankiewicz H, Goldstein R, Drukker A. Fish oil treatment of hyperlipidemia in children and adolescents receiving renal replacement therapy. Pediatrics 1991; 88:265-8.
56. Guarnieri G, Toigo G, Crapesi L, Situlin R, Del Bianco MA, Corsi M, et al. Carnitine metabolism in chronic renal failure. Kidney Int 1987; 32(Suppl 22):S116-27.
57. Moorthy AV, Rosenblum M, Rajarm R, Shug AL. A comparison of plasma and muscle carnitine levels in patients on peritoneal or hemodialysis for chronic renal failure. Am J Nephrol 1983; 3:205-8.
58. Lacour B, Di Giulio S, Chanard J, Ciancioni C, Haguet M, Lebkiri B, et al. Carnitine improves lipid anomalies in hemodialysis patients. Lancet 1980; 2:763-5.
59. Bertoli M, Battistella PA, Vergani L, Naso A, Gasparotto ML, Romagnoli GF, et al. Carnitine deficiency induced during hemodialysis and hyperlipidemia: effect of replacement therapy. Am J Clin Nutr 1981; 34:1496-500.
60. Gloggler A, Bulla M, Furst P. Effect of low dose supplementation of L-carnitine on lipid metabolism in hemodialyzed children. Kidney Int 1989; 36(Suppl 27): S256-8.
61. Nilsson-Ehle P, Cederblad G, Fagher B, Monti M, Thysell H. Plasma lipoproteins, liver function and glucose metabolism in hemodialysis patients: lack of effect of L-carnitine supplementation. Scand J Clin Lab Invest 1985; 45:179-84.
62. Golper TA, Wolfson M, Ahmad S, Hirschberg R, Kurtin P, Katz LA, et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients: I. Carnitine concentrations and lipid effects. Kidney Int 1990; 38:904-11.
63. Chan MK, Persaud JW, Varghese Z, Baillod RA, Moorhead JF. Response patterns to L-carnitine in patients on maintenance hemodialysis. Nephron 1982; 30:240-3.
64. Weschler A, Avram M, Levin M, Better OS, Brook JG. High dose of L-carnitine increases platelet aggregation and plasma triglyceride levels in uremic patients on hemodialysis. Nephron 1984; 38:120-4.
65. Wanner C, Forstner-Wanner S, Schaeffer G, Schollmeyer P, Horl WH. Serum free carnitine, carnitine esters and lipids in patients on peritoneal dialysis and hemodialysis. Am J Nephrol 1986; 6:206-11.
66. Warady BA, Borum P, Stall C, Millspaugh J, Taggart E, Lum G. Carnitine status of pediatric patients on continuous ambulatory peritoneal dialysis. Am J Nephrol 1990; 10:109-14.
67. Sacks FM, Pfeffer M, Moye L, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-9.
68. Summary of the second report of the National Cholesterol Educational Program (NCEP). Expert panel on detection evaluation and treatment of high blood cholesterol in adults. JAMA 1993; 269:3015-23.
69. Pollack C, Wyndham R, Collett P, Elder G, Field M, Kalowsky S, et al. Effects of erythropoietin therapy on the lipid profile in end stage renal disease. Kidney Int 1994; 45:897-902.
70. D'Amico G, Gentile MG. Influence of diet on lipid abnormalities in human renal disease. Am J Kidney Dis 1993; 22:151-7.
71. Avram M, Blaustein D. Causes, risks and therapy of hyperlipidemia in chronic dialysis patients. Semin Dial 1997; 10:267-71.